MNKD (MannKind) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNKD MannKind Corp MNKD
66 GF Score
Price $4.20
GF Value $7.40
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MannKind Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

MNKD vs ABSI, ORIC, ARDX: Short Interest Comparison

For the Biotechnology subindustry, MannKind's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MannKind Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MannKind's Short Interest distribution charts can be found below:

* The bar in red indicates where MannKind's Short Interest falls into.


MNKD
66GF Score
MannKind Corp MNKD
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MannKind (MNKD) Overvalued in 2026?

Based on GuruFocus' analysis, MannKind stock appears to be undervalued. The current stock price of $4.20 is trading 43.2% below its estimated GF Value™ of $7.40. GuruFocus considers MannKind to be Possible Value Trap.

Key valuation signals for MNKD:

  • Short Interest:
  • GF Value™: $7.40 vs. price of $4.20 (43.2% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the MNKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MannKind Business Description

Other Exchanges NNFN:Germany
Address 1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
66GF Score

Get the complete analysis for MNKD

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.20
Price
$7.40
GF Value